Bimekizumab versus secukinumab in plaque psoriasis: Reduction in body surface area affected by psoriasis translates into benefits in patient-perceived itching, skin pain, and scaling and health-related quality of life in the BE RADIANT phase 3b trial

被引：0
|
作者：
Augustin, Matthias [1 ]
Gooderham, Melinda [2 ,3 ]
Gottlieb, Alice B. [4 ]
机构：
[1] Univ Med Ctr Hamburg Eppendorf UKE, Inst Hlth Serv Res Dermatol & Nursing IVDP, Hamburg, Germany
[2] Prob Med Res, Skin Ctr Dermatol, Peterborough, ON, Canada
[3] Queens Univ, Kingston, ON, Canada
[4] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2022年 / 87卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
31069
引用
收藏
页码：AB25 / AB25
页数：1
相关论文
共 11 条
  • [1] Bimekizumab versus secukinumab for the treatment of nail psoriasis in patients with moderate to severe plaque psoriasis: Results from the BE RADIANT phase 3b trial
    Eyerich, Kilian
    Gottlieb, Alice B.
    Piaserico, Stefano
    Beissert, Stefan
    Gooderham, Melinda
    Kirby, Brian
    Tilt, Nicola
    Madden, Cynthia
    Wiegratz, Susanne
    de Cuyper, Dirk
    Elewski, Boni
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB22 - AB22
  • [2] Bimekizumab versus Secukinumab for the Treatment of Nail Psoriasis in Patients with Moderate to Severe Plaque Psoriasis: Results from the BE RADIANT Phase 3b Trial
    Eyerich, Kilian
    Gottlieb, Alice B.
    Piaserico, Stefano
    Beissert, Stefan
    Gooderham, Melinda
    Kirby, Brian
    Tilt, Nicola
    Madden, Cynthia
    Wiegratz, Susanne
    de Cuyper, Dirk
    Merola, Joseph F.
    Elewski, Boni
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 4467 - 4469
  • [3] Bimekizumab versus secukinumab in plaque psoriasis: Psoriasis Symptoms and Impacts Measure (P-SIM) responses accompanying achievement of complete skin clearance in the phase 3b BE RADIANT trial
    Gottlieb, Alice B.
    Langley, Richard G.
    Warren, Richard B.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB25 - AB25
  • [4] Itching in patients with moderate to severe plaque psoriasis: The relationship between improvements in Psoriasis Area and Severity Index and patient-reported symptoms in the BE RADIANT phase 3b trial
    Augustin, Matthias
    Langley, Richard G.
    Warren, Richard B.
    Lebwohl, Mark
    Elewski, Boni
    Crowley, Jeffrey
    Warham, Rhys
    Kaspar, Markus
    Wiegratz, Susanne
    Ciaravino, Valerie
    Gottlieb, Alice B.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB184 - AB184
  • [5] Bimekizumab versus secukinumab efficacy across subgroups of patients with moderate to severe plaque psoriasis: Results from the multicentre, randomised, double-blinded phase 3b BE RADIANT trial
    Shumack, Stephen
    Blauvelt, Andrew
    Iversen, Lars
    McBride, Sandy
    Gooderham, Melinda
    Staubach-Renz, Petra
    Yamauchi, Paul
    Staelens, Fabienne
    Vanvoorden, Veerle
    White, Katy
    Gisondi, Paolo
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2023, 64 : 17 - 18
  • [6] Bimekizumab early treatment response translates into cumulative health-related quality of life benefits in patients with moderate to severe plaque psoriasis: Pooled results from three phase 3 trials
    Rubel, Diana
    Gordon, Kenneth B.
    Sebastian, Michael
    Feldman, Steven R.
    Eusebi, Paolo
    Wixted, Krista
    Madden, Cynthia
    Gomez, Natalie Nunez
    Ciaravino, Valerie
    Radtke, Marc
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2023, 64 : 19 - 20
  • [7] Secukinumab is superior to ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: CLARITY, a randomized, controlled, phase 3b trial
    Bagel, Jerry
    Nia, John
    Hashim, Peter W.
    Patekar, Manmath
    Hugot, Sophie
    Sheng, Kuan
    Xia, Summer
    Gilloteau, Isabelle
    Blauvelt, Andrew
    Lebwohl, Mark
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB274 - AB274
  • [8] Secukinumab is superior to ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: CLARITY, a randomized, controlled, phase 3b trial
    Bagel, J.
    Nia, J.
    Hashim, P.
    Patekar, M.
    de Vera, A.
    Hugot, S.
    Sheng, K.
    Xia, S.
    Gilloteau, I.
    Blauvelt, A.
    Lebwohl, M.
    Bian, M.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2019, 60 : 17 - 18
  • [9] Bimekizumab early treatment response translates into cumulative benefits in health-related quality of life in patients with moderate to severe plaque psoriasis: Pooled results from three multicenter, randomized, double-blinded phase 3 trials
    Gordon, Kenneth B.
    Sebastian, Michael
    Feldman, Steven R.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB24 - AB24
  • [10] P94 Bimekizumab early treatment response translated into cumulative benefits in health-related quality of life in patients with moderate-to-severe plaque psoriasis: results from 2years of the BE RADIANT phase IIIb trial
    Hampton, Philip
    Brunner, Patrick
    Ghoreschi, Kamran
    Boehncke, Wolf-Henning
    Warham, Rhys
    Ciaravino, Valerie
    Szilagyi, Balint
    Staelens, Fabienne
    Foulkes, Amy
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
12